EGFR and non-small cell lung carcinoma: Recent studies have highlighted the critical role of YAP in the survival of DTPs, particularly in EGFR-mutant non-small cell lung cancer (NSCLC), where YAP activation suppresses the expression of pro-apoptotic BMF, enabling apoptosis evasion [14].